Balance between IL-1 beta, TNF-alpha, and their specific inhibitors in chronic renal failure and maintenance dialysis. Relationships with activation markers of T cells, B cells, and monocytes.
Patients with end-stage renal disease present an immunodeficiency that paradoxically coexists with activation of most immunocompetent cells, and the roles of chronic uremia and maintenance dialysis are poorly understood. We determined circulating levels of IL-1 beta and IL-1Ra, TNF-alpha and its soluble receptors (TNF-sR55 and TNF-sR75), and activation markers of T cells (soluble CD25), B cells (soluble CD23), and monocytes (neopterin) in a large cohort of undialyzed patients at various stages of chronic renal failure and in dialyzed patients on maintenance hemodialysis or chronic peritoneal dialysis. The progression of uremia was associated with a gradual increase in soluble CD25, CD23, and especially neopterin levels. Although IL-1 beta could not be detected, IL-1Ra levels were significantly increased from the earliest stage of renal failure. Plasma levels of TNF-alpha, TNF-sR55, and TNF-sR75 progressed with the severity of renal failure and correlated with soluble CD25, CD23, and neopterin levels, whereas IL-1Ra levels correlated exclusively with TNF-sR55 levels. Compared with undialyzed patients, levels of IL-1 beta were higher in patients on maintenance hemodialysis, whereas those of IL-1Ra were lower and decreased further at the end of dialysis sessions. In contrast, both TNF-sR55 and TNF-sR75 levels were significantly higher than in undialyzed patients and increased further at the end of dialysis sessions in the absence of an increase of TNF-alpha. Such an imbalance between cytokines and their inhibitors may play a pivotal role in the multifaceted process of immune dysfunction.
Descamps-Latscha
B
B
INSERM Unit 25, Necker Hospital, Paris, France.
Herbelin
A
A
Nguyen
A T
AT
Roux-Lombard
P
P
Zingraff
J
J
Moynot
A
A
Verger
C
C
Dahmane
D
D
de Groote
D
D
Jungers
P
P
D001402:B-Lymphocytes / Q000276:immunology; D001708:Biopterins / Q000031:analogs & derivatives / Q000097:blood; D003430:Cross-Sectional Studies; D006801:Humans; D053590:Interleukin 1 Receptor Antagonist Protein; D007375:Interleukin-1 / Q000037:antagonists & inhibitors / Q000097:blood*; D007376:Interleukin-2 / Q000097:blood; D007676:Kidney Failure, Chronic / Q000276:immunology* / Q000628:therapy; D009000:Monocytes / Q000276:immunology; D019798:Neopterin; D010531:Peritoneal Dialysis, Continuous Ambulatory / Q000009:adverse effects; D017455:Receptors, IgE / Q000378:metabolism; D015375:Receptors, Interleukin-2 / Q000378:metabolism; D018124:Receptors, Tumor Necrosis Factor / Q000378:metabolism; D006435:Renal Dialysis / Q000009:adverse effects*; D012795:Sialoglycoproteins / Q000097:blood; D013601:T-Lymphocytes / Q000276:immunology; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors / Q000378:metabolism*
C507763:IL1RN protein, human; D053590:Interleukin 1 Receptor Antagonist Protein; D007375:Interleukin-1; D007376:Interleukin-2; D017455:Receptors, IgE; D015375:Receptors, Interleukin-2; D018124:Receptors, Tumor Necrosis Factor; D012795:Sialoglycoproteins; D014409:Tumor Necrosis Factor-alpha; D001708:Biopterins; D019798:Neopterin